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Thrombotic occlusion or thrombus embolization plays a major role in the pathogenesis of vascular events including ischaemic or embolic stroke and myocardial infarction. Patients with acute coronary syndromes (ACSs) or ischaemic stroke are routinely treated with aspirin and a P2Y12 receptor blocker such as clopidogrel [dual anti platelet therapy (DAPT)], while those with atrial fibrillation are treated with anticoagulants such as coumadin or, more recently, novel oral anticoagulants (NOACs) such as dabigatran, apixaban, or rivaroxiban. Such therapies are considered essential for primary and secondary prevention of ischaemic events.
Bleeding is a well-known side effect of these therapies, and major or minor bleeds are clinically what are most commonly noted by physicians as side effects. However, as atherosclerotic plaques progress, it is well known that microbleeds or intraplaque haemorrhages (IPHs) inside of advanced atherosclerotic plaques are an important risk factor for plaque progression (Take home figure). Red cell membranes are rich in free cholesterol and their presence inside atherosclerotic lesions is thought to increase plaque bulk and necrotic core size, leading to plaque progression. Despite their widespread use, the effect and duration of antiplatelet and anticoagulant therapies on plaque composition remains relatively unknown. Yet, it seems logical to be concerned that anticoagulants may increase IPH and plaque progression, thereby causing an increase in events, especially in individuals who require long-term treatment.
Technological advances in non-invasive imaging, especially magnetic resonance imaging (MRI), have allowed a more detailed characterization of plaque components, especially for the examination of carotid artery plaques. Although limited by methodological concerns, previous work has suggested a potential link between the use of both antiplatelet and anticoagulant therapies and the occurrence of IPH. 2 Of course, such studies are confounded by the fact that those with more advanced atherosclerosis tend to be sicker patients requiring antithrombotic medications, and would also be more likely to have IPH. In this issue of the European Heart Journal, Mujaj et al. present data from a substudy of the population-based Rotterdam Study. On the basis of pre-screening with carotid ultrasound, 1740 patients with carotid atherosclerosis (intima media thickness >2.5 mm) on ultrasound underwent carotid MRI. 3 The investigators found that carotid IPH was more frequently found in users of antithrombotic therapies compared with never-users. Current and past use of both vitamin K antagonists (VKAs) and antiplatelet agents was associated with a nonstatistically significant trend towards higher presence of IPH. No associations were found between use of either VKAs or antiplatelet agents and the higher presence of lipid core or calcification. While use of VKA for 3 months or less was not associated with the presence of IPH, a longer duration of use (i.e. >3 months) was associated with IPH, and this relationship became more prominent when adjusted for international normalized ratio (INR) >2.97. Overall, the use of antiplatelet agents for less than or greater than 30 months was not related to the presence of IPH. However, daily dosages >1.0 for antiplatelet agents were significantly associated with the presence of IPH. 3 While the results of this population-based study seem to suggest a potential harmful effect of antithrombotic treatment on carotid atherosclerotic plaque composition, a closer analysis is warranted. In analysing this study, one must consider important limitations. First, observational studies are subject to important confounders and biases, which might not be able to be corrected for by statistical methods. It is likely that antiplatelet agents or VKAs would have been used more commonly in patients with pre-existing vascular disease, and that these patients might have also been more likely to have IPH. This would confound any attempt to find an association between use of these agents and IPH, and might not be able to be adjusted for. When the analysis was restricted to those without a history of cardiovascular disease, the association appeared to get weaker with mostly non-significant trends. Second, the study is missing important endpoints such as reporting of strokes and transient ischaemic attacks, which would help to validate the authors' concerns. Ultimately, the use of pharmacological antithrombotic agents has been repeatedly shown to decrease cardiovascular events. Antiplatelet agents and anticoagulants must be evaluated within the context of net benefit. Lastly, how accurate is MRI at assessing plaque composition? Validation of MRI for the detection of IPH has been done using carotid endarterectomy histology specimens. Some parts of the analysis on plaque composition shown in this study do not make sense. IPH is known to increase plaque progression by increasing free cholesterol within the necrotic core. In previous pathological as well as MRI studies, it has been reported that there is a good correlation between the presence of IPH and an increase in necrotic core size/volume. 4, 5 The current study contradicts most other studies that have correlated MRI presence of IPH with a larger necrotic core. 6, 7 In the current study, no association was found between the use of antiplatelet or VKA agents and changes in calcium levels. VKA antagonists are well known to increase vascular calcification due to inhibition of the enzyme matrix gamma carboxyglutamate gla protein, a known inhibitor of calcification. alone. More recently introduced P2Y12 inhibitors, such as prasugrel and ticagrelor, were superior to clopidogrel in the TRITON and PLATO trials. 11, 12 However, the evidence for DAPT in patients with stable coronary heart disease is much less convincing. In the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial, the addition of clopidogrel to aspirin in patients with established or at high-risk for cardiovascular disease did not reduce events, and was associated with increased severe bleeding. 13 Similar results were seen in the Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of AspirinThrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial, in which the combination of ticagrelor plus aspirin reduced the incidence of major adverse vascular events vs. aspirin alone, but at the expense of increased major bleeding. 14 When clinicians prescribe DAPT, they need to be careful about the clinical indication for such therapies and should be aware of the potential for harm, as suggested by Mujaj et al.
VKAs have never been a cornerstone for secondary or primary prevention of coronary events, primarily because of the excess risk of major bleeds, but are still used regularly in those with atrial fibrillation to prevent thromboembolic events. 15 Even though their use is associated with a multitude of potential complications, an excess risk of atherosclerotic events is not considered to be one of them.
More recently, the use of direct factor Xa inhibitors has been studied for the prevention of vascular events. The Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary SyndromeThrombolysis in Myocardial Infarction 52 (ATLAS ACS 2-TIMI 51) study randomly assigned patients with recent ACS to either twice-daily doses of 2.5 or 5 mg of rivaroxiban or placebo (although those with prior ischaemic stroke or transient ischaemic attack were excluded). 16 All patients received DAPT with aspirin, and clopidogrel or ticlopidine, with a primary endpoint of cardiovascular death, myocardial infarction (MI), and stroke. Rivaroxiban (at both doses combined) significantly reduced the rate of the primary endpoint with improvement in survival at the 2.5 mg dose, with significantly increased rate of TIMI major bleeding. No significant effect on stroke was seen, but both doses significantly reduced the incidence of MI. More, recently in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial, participants with stable atherosclerotic vascular disease were randomly assigned to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). 17 The primary outcome of the composite of cardiovascular death, stroke, or MI occurred in fewer patients in the rivaroxaban plus aspirin group vs. the aspirin alone group. Overall, these trials suggest that there is emerging evidence of the efficacy for NOACs (at least rivaroxaban) for the prevention of cardiovascular events.
In conclusion, Mujaj et al. ask an interesting scientific question about the relationship between antithrombotic use and the incidence of carotid IPH using MRI in an observational study. Their data are far from definite, but suggest a potential association between the use of antithrombotic agents and the increased presence of IPH. Residual confounding factors cannot be ruled out and remain a large weakness of the current study. Nevertheless, this data must be understood within the larger context of the use of antiplatelet and anticoagulant therapies for the prevention of cardiovascular events, where the benefit of hard clinical endpoints is what really matters. In analysing the myriad trials done in this area, there is a clear clinical benefit of these therapies. More carefully designed studies with clinical followup are warranted before the effect of these therapies on plaque composition can be considered as an important endpoint.
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